Management of optic neuritis and impact of clinical trials: An international survey

2009 ◽  
Vol 276 (1-2) ◽  
pp. 69-74 ◽  
Author(s):  
Valérie Biousse ◽  
Olivier Calvetti ◽  
Carolyn D. Drews-Botsch ◽  
Edward J. Atkins ◽  
Busaba Sathornsumetee ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Optic Neuritis ◽  
International Survey

Optic Neuritis Revisited

2006 ◽  
Vol 8 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Fiona Costello
Keyword(s):  
Magnetic Resonance Imaging ◽  
Multiple Sclerosis ◽  
Clinical Trials ◽  
Optic Neuritis ◽  
Large Scale ◽  
Inflammatory Process ◽  
Resonance Imaging ◽  
Prognostic Information ◽  
Future Risk ◽  
The Relationship

Optic neuritis (ON) refers to a retrobulbar inflammatory process of the optic nerve and frequently manifests as the first clinical symptom of multiple sclerosis (MS). The diagnosis is established on clinical grounds and is complemented by magnetic resonance imaging, which provides prognostic information about the future risk of MS. The results of large-scale clinical trials have enhanced understanding of the relationship between ON and MS.

scholarly journals Management of Optic Neuritis in Canada: Survey of Ophthalmologists and Neurologists

2008 ◽  
Vol 35 (2) ◽  
pp. 179-184 ◽  
Author(s):  
Edward J. Atkins ◽  
Carolyn D. Drews-Botsch ◽  
Nancy J. Newman ◽  
Olivier Calvetti ◽  
Seegar Swanson ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Optic Neuritis ◽  
Randomized Clinical Trials ◽  
Mail Survey ◽  
Standard Of Care ◽  
High Dose ◽  
Acute Optic Neuritis ◽  
Disease Modifying ◽  
Disease Modifying Agents ◽  
The Impact

ABSTRACTBackground:Acute isolated optic neuritis is often the first manifestation of multiple sclerosis (MS), and its management remains controversial. Over the past decade, with the advent of new disease-modifying agents, management of isolated optic neuritis has become more complicated.Objectives:To evaluate the current practice patterns of Canadian ophthalmologists and neurologists in the management of acute optic neuritis, and to evaluate the impact of recently published randomized clinical trials.Design:Mail survey.Methods:All practicing ophthalmologists and neurologists in Canada were mailed a survey evaluating the management of isolated acute optic neuritis and familiarity with recent clinical trials. Surveys for 1158 were mailed, and completed surveys were collected anonymously through a datafax system. Second and third mailings were sent to non-respondents 6 and 12 weeks later.Results:The final response rate was 34.5%. Although many acute optic neuritis patients initially present to ophthalmologists, neurologists are the physicians primarily managing these patients. Ordering magnetic resonance imaging, and treating with high dose intravenous steroids has become the standard of care. However, 15% of physicians (14% of ophthalmologists and 16% of neurologists) continue to prescribe low dose oral steroids, and steroids are being given for reasons other than to shorten the duration of visual symptoms by 73% of ophthalmologists and 50% of neurologists. More neurologists than ophthalmologists are familiar with recent clinical trials involving disease-modifying agents.Conclusion:Although the management of acute optic neuritis has been evaluated in large clinical trials that were published in major international journals, some ophthalmologists and neurologists are not following evidence-based recommendations.

Localization of Gallium-67 in Peritoneal Cells by Electron Microscopic Autoradiography

1973 ◽  
Vol 31 ◽  
pp. 404-405
Author(s):  
D. C. Swartzendruber ◽  
Norma L. Idoyaga-Vargas
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Tumor Tissue ◽  
Soft Tissue Tumors ◽  
Clinical Usefulness ◽  
Electron Microscopic ◽  
Normal Cells ◽  
Electron Microscopic Autoradiography ◽  
Peritoneal Cells ◽  
Gallium 67

The radionuclide gallium-67 (67Ga) localizes preferentially but not specifically in many human and experimental soft-tissue tumors. Because of this localization, 67Ga is used in clinical trials to detect humar. cancers by external scintiscanning methods. However, the fact that 67Ga does not localize specifically in tumors requires for its eventual clinical usefulness a fuller understanding of the mechanisms that control its deposition in both malignant and normal cells. We have previously reported that 67Ga localizes in lysosomal-like bodies, notably, although not exclusively, in macrophages of the spocytaneous AKR thymoma. Further studies on the uptake of 67Ga by macrophages are needed to determine whether there are factors related to malignancy that might alter the localization of 67Ga in these cells and thus provide clues to discovering the mechanism of 67Ga localization in tumor tissue.

Patients' satisfaction in clinical trials

2000 ◽  
Vol 248 (6) ◽  
pp. 441-442 ◽  
Author(s):  
L. Terenius
Keyword(s):  
Clinical Trials ◽  
Patients Satisfaction
Sign in / Sign up

Export Citation Format

Share Document